STOCK TITAN

Incannex Healthcare Ltd - IXHL STOCK NEWS

Welcome to our dedicated page for Incannex Healthcare news (Ticker: ixhl), a resource for investors and traders seeking the latest updates and insights on Incannex Healthcare stock.

Incannex Healthcare Ltd (IXHL) is a clinical-stage biopharmaceutical innovator developing novel cannabinoid and psychedelic-assisted therapies for chronic medical conditions. This dedicated news hub provides investors and healthcare professionals with essential updates on the company's research advancements and operational milestones.

Access authoritative information about IXHL's clinical trials, regulatory developments, and strategic partnerships. Our curated collection includes press releases on sleep apnea therapies, inflammatory disease treatments, and neurological disorder research – all critical to understanding the company's progress in psychedelic medicine and cannabinoid science.

Key updates cover therapeutic program developments, Australian medicinal cannabis license utilization, and financial strategy implementations. Stay informed about IXHL's pioneering work through verified announcements regarding clinical-stage breakthroughs and research collaborations.

Bookmark this page for direct access to Incannex Healthcare's official communications. Regularly updated content ensures you maintain current awareness of their innovative approaches to addressing unmet medical needs through advanced pharmaceutical research.

Rhea-AI Summary
Incannex Healthcare Inc (Nasdaq: IXHL) is pleased to announce that Clarion Clinic’s Head of Psychiatry, Professor Suresh Sundram, has been approved by the TGA to prescribe MDMA for Post-traumatic Stress Disorder and psilocybin for Treatment-resistant Depression. The clinic in Melbourne is now open and represents Australia’s leading track record in psychedelic-assisted therapies. The TGA down-scheduled MDMA and psilocybin for use in the treatment of PTSD and TRD, permitting their use in clinical service delivery through the Authorised Prescriber Scheme.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.4%
Tags
none
-
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has announced the commencement of patient dosing in the Phase 2 clinical trial for IHL-675A, a combination drug candidate for rheumatoid arthritis. The trial aims to assess pain and function relative to baseline and will enroll 128 participants across 10 study sites in Australia. IHL-675A is a proprietary combination of Hydroxychloroquine Sulphate and cannabidiol, with well-characterized anti-inflammatory activity. The trial will monitor safety and efficacy outcomes, including inflammatory biomarkers and joint inflammation and damage via MRI. IHL-675A is a potential treatment for other inflammatory conditions such as inflammatory bowel disease, COPD, and asthma.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.23%
Tags
-
Rhea-AI Summary
Incannex Healthcare Inc. completed dosing and treatment protocols for all 72 participants in the PsiGAD-1 clinical trial evaluating its psilocybin treatment program for patients with generalized anxiety disorder. The company anticipates topline results within Q1 2024 and is well-advanced in the FDA IND application process. An independent documentary covering Monash Clinical Psychedelic Lab and PsiGAD research program will be released by SBS television network in late February 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.12%
Tags
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) has received IRB approval for the protocol of its Phase 2/3 clinical trial for the drug candidate IHL-42X to treat obstructive sleep apnea (OSA). The trial will assess safety and efficacy in OSA patients who are intolerant, non-compliant, or naïve to positive airway pressure (PAP). The study aims to recruit at least 560 patients across the United States, Germany, Spain, and Finland. The Phase 2/3 trial has already begun startup with 24 sites selected in the United States, 13 in Germany, 4 in Spain, and 2 in Finland. IHL-42X has shown promising results in a Phase 2 proof-of-concept study, reducing the apnea hypopnea index (AHI) by over 50% at the optimal dose, improving oxygen desaturation index, sleep efficiency, and patient-reported sleep quality.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
-
Rhea-AI Summary
Incannex Healthcare Ltd (Nasdaq: IXHL) has received Human Research Ethics Committee (HREC) endorsement for administration of psychedelic-assisted therapies for TRD and PTSD. The Melbourne clinic fit-out is complete, and the clinical and administrative teams are in place. The clinic is the first dedicated Psychedelic-assisted therapy clinic in Australia and has received a substantial number of expressions of interest in treatment submissions from potential patients since opening its application process earlier this year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.08%
Tags
none
-
Rhea-AI Summary
Incannex Healthcare Inc. (Nasdaq: IXHL) is developing IHL-42X, a promising drug candidate for obstructive sleep apnea (OSA) treatment. The drug has shown significant efficacy in reducing apnea hypopnea index (AHI) in Phase 2 clinical trials, with potential to address a market of 936 million affected adults worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-22.45%
Tags
Rhea-AI Summary
Incannex Healthcare Inc. (NASDAQ: IXHL) successfully completed its redomiciliation from Australia to the United States, with shares of common stock expected to commence trading on Nasdaq under the symbol 'IXHL' on November 30, 2023. The company will now be subject to the reporting requirements of the SEC and corporate governance rules of Nasdaq.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Incannex Healthcare Limited (ASX: IHL) (NASDAQ: IXHL) announces the approval of the scheme of arrangement for the proposed re-domiciliation from Australia to the United States. The Federal Court of Australia has made orders approving the scheme, with Incannex Healthcare Inc. becoming the ultimate parent company. The company has applied to suspend quotation and trading of shares on ASX, with ADRs continuing to trade on Nasdaq until the implementation date. Shareholders and optionholders will be entitled to receive the Scheme consideration on the implementation date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.28%
Tags
none
-
Rhea-AI Summary
Incannex to present at H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.56%
Tags
none
Rhea-AI Summary
Incannex Healthcare prepares IND application for psilocybin therapy, positive interim analysis predicts significant benefit in Phase 2 trial
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.26%
Tags
Incannex Healthcare Ltd

Nasdaq:IXHL

IXHL Rankings

IXHL Stock Data

16.53M
19.13M
30.57%
1.25%
0.43%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
Australia
DOCKLANDS, VICTORIA